Protara Therapeutics Inc (NAS:TARA)
$ 5.51 0.01 (0.18%) Market Cap: 189.10 Mil Enterprise Value: 112.00 Mil PE Ratio: 0 PB Ratio: 1.39 GF Score: 40/100

Protara Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript

Sep 11, 2023 / 01:30PM GMT
Release Date Price: $2.12 (-1.35%)
Andres Maldonado
H.C. Wainwright & Co., LLC - Analyst

Good morning, everyone, and welcome back to H.C. Wainwright's 25th Annual Global Investment Conference. My name is Andres Maldonado. I'm a biotech analyst here at the firm, and I'd like to introduce our next presenter. I'd like to welcome Jesse Shefferman, who's the CEO of Protara Therapeutics. Welcome, and the floor is yours.

Jesse Shefferman
Protara Therapeutics, Inc. - Co-founder, Director, CEO

Thank you very much, and thanks to the H.C. Wainwright team for having Protara here. I'm going to try and move quickly through a lot of material here. We've got a short amount of time.

A quick introduction on Protara Therapeutics. We are a New York City-based biotechnology company focused on oncology and rare diseases. We have three programs across our portfolio. Our lead asset is TARA-002. It is a bacterial immunopotentiator first developed in the 1970s in Japan, which we are now repurposing for non-muscle-invasive bladder cancer as well as a rare structural malformations disorder called lymphatic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot